Clinical trials
Fibrotic Interstitial Lung Disease clinical trials
Below are recruiting fibrotic interstitial lung disease clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06182748Recruiting
Physical activity and lung scarring
This study tests if a supervised exercise program, 3 times a week, helps people with lung scarring (fibrosing interstitial lung disease). It may improve your breathing and quality of life.
Bobigny, Seine Saint DenisAges 18 years+ - NCT06655090Recruiting
Early detection and treatment study for lung scarring disease
This study looks at how to find and treat fibrotic interstitial lung disease (a condition where lung tissue becomes scarred and stiff) as early as possible. It may help people with this type of lung disease get better care.
Beijing, Beijing MunicipalityAges Any age - NCT07673237Recruiting
Remote monitoring for interstitial lung disease
This study tests whether using remote monitoring devices and apps at home can help track your lung health between clinic visits. It may help you stay connected with your care team and catch changes sooner.
San Francisco, CaliforniaAges 18 years+ - NCT06702228Recruiting
Precision care for pulmonary fibrosis in Ireland
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
DublinAges 18–85 - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT06732674Recruiting
Home-based care for lung disease in rheumatic conditions
This trial tests whether people with lung disease caused by a rheumatic condition can safely manage their care at home using a smartphone or tablet. It aims to see if home monitoring is as effective as in-person visits for keeping your lungs healthy.
OsloAges 18 years+ - NCT07540988RecruitingPhase 3
Testing Nerandomilast for Scarring Lung Disease
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
Birmingham, AlabamaAges 18 years+ - NCT07512687Enrolling by invitation
Portable Oxygen During Daily Activity for Lung Disease
This study tests whether using portable oxygen during everyday activities helps people with certain lung diseases (like pulmonary fibrosis or COPD) who only experience low oxygen levels when moving around. Researchers want to see if a portable oxygen device improves how well participants can function and feel during daily life.
Buffalo, New YorkAges 18–85 - NCT07486206Recruiting
Optimizing follow-up for interstitial lung disease
This trial tests a new way to organize follow-up visits for people with interstitial lung disease (a group of lung conditions). It aims to make care simpler and more effective for patients who are already on treatment.
Granollers, BarcelonaAges 18 years+ - NCT07482917Recruiting
Streamlining the diagnosis of interstitial lung disease
This study is testing a new way to speed up the diagnosis of interstitial lung disease (a group of lung scarring conditions). If you have symptoms or scan findings that suggest ILD but haven't been fully diagnosed yet, this trial may help you get a faster, clearer answer.
Granollers, BarcelonaAges 18 years+ - NCT07473700RecruitingPhase 2
Study of TX000045 for lung scarring and high blood pressure in the lungs
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
Phoenix, ArizonaAges 18–80 - NCT07466420Recruiting
Quercetin for fibrotic lung disease
This trial tests whether taking quercetin, a natural supplement, can help people with fibrotic interstitial lung diseases (a group of conditions that cause scarring in the lungs). If you have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic ILD and are on standard treatments, you may be able to join.
Heraklion, CreteAges 18 years+ - NCT06122233Recruiting
Digital self-management for fibrotic lung disease
This trial tests whether a digital self-management program (using a smartphone or tablet) helps people with fibrotic interstitial lung disease better manage their symptoms and quality of life. If you have this lung condition and can use a mobile device, this study could offer you extra support at home.
Sydney, New South WalesAges 18 years+ - NCT07175038RecruitingPhase 2
Study of a new pill for pulmonary hypertension
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Phoenix, ArizonaAges 18–80 - NCT07179380RecruitingPhase 3
Inhaled treprostinil for pulmonary hypertension related to interstitial lung disease
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
Phoenix, ArizonaAges 18 years+ - NCT06326957Recruiting
Online program for chronic breathlessness
This trial tests an internet-based self-guided program to help adults with chronic breathlessness. It is designed for people who still feel short of breath despite treatment for conditions like COPD, lung disease, or cancer.
LondonAges 18–110 - NCT06751069Recruiting
Home exercise and coaching for lung scarring
This study tests a home-based exercise and health coaching program for people with scarring in their lungs (fibrotic ILD). The goal is to see if doing rehab at home, with support from a coach, can help you feel better and breathe easier.
Scottsdale, ArizonaAges 18 years+ - NCT06714123RecruitingPhase 2
Senicapoc for worsening lung scarring
This trial tests if the drug senicapoc can help people whose lung scarring (pulmonary fibrosis) is getting worse despite standard care. It aims to slow down the decline in lung function.
Aarhus NAges 18 years+ - NCT06644144Recruiting
P4O2: A study for people with lung scarring
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
Amsterdam, North HollandAges 18–80 - NCT06626438Recruiting
Treating lung scarring by focusing on each person's problems
This study looks at how to better treat different types of lung scarring (fibrotic ILD) by focusing on each person's specific problems. It is for adults who are already being treated for a fibrotic ILD at one of two hospitals in Perth, Australia.
Perth, Western AustraliaAges 18 years+ - NCT06572384RecruitingPhase 3
Belimumab for lung scarring in autoimmune disease
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
Los Angeles, CaliforniaAges 18 years+ - NCT06574581RecruitingPhase 1/Phase 2
Adipose stem cells for connective tissue disease with lung scarring
This trial tests whether stem cells from fat tissue can help people with connective tissue diseases (like lupus or scleroderma) whose lung scarring has worsened despite standard treatments. It aims to slow or stop lung damage.
TaichungAges 20–80 - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Birmingham, AlabamaAges 18 years+ - NCT06036719Recruiting
Lung scarring study from childhood to old age
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
Paris, Île-de-France RegionAges Any age
Hear when a new Fibrotic Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrotic interstitial lung disease?
- Yes. Clin2 currently lists 37 recruiting fibrotic interstitial lung disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrotic interstitial lung disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrotic interstitial lung disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.